Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology
- 24 April 2014
- journal article
- research article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 16 (6) , 1-9
Abstract
Since 1976, the US Food and Drug Administration (FDA) has used the premarket approval (PMA) process to approve high-risk medical devices, including implantable cardioverter defibrillators (ICDs), coronary stents, and artificial heart valves. The PMA process is widely viewed as a rigorous evaluation of device safety and effectiveness, though recent recalls—most notably related to underperforming ICD leads—have raised concerns about whether physicians and patients should sometimes be more wary about devices approved via this pathway. The FDA must utilize a “least burdensome” approach to approve new medical devices, and many widely used device models have been approved as supplements to existing PMA-approved devices with limited clinical testing. A recent Supreme Court ruling has made it difficult for patients harmed by unsafe PMA-approved devices to seek damages in court. Cardiologists who utilize high-risk medical devices should be aware that FDA approval of new devices relies on variable levels of evidence and does not necessarily indicate improved effectiveness over existing models. Clinician and patient engagement in postmarket surveillance and comparative effectiveness research remains imperative.Keywords
This publication has 25 references indexed in Scilit:
- Postmarket surveillance for medical devices: America's new strategyBMJ, 2012
- Early Detection of an Underperforming Implantable Cardiovascular Device Using an Automated Safety Surveillance ToolCirculation: Cardiovascular Quality and Outcomes, 2012
- Regulation of Medical Devices in the United States and European UnionNew England Journal of Medicine, 2012
- Implantation Trends and Patient Profiles for Pacemakers and Implantable Cardioverter Defibrillators in the United States: 1993-2006Pacing and Clinical Electrophysiology, 2010
- Premarket Clinical Evaluation of Novel Cardiovascular Devices: Quality Analysis of Premarket Clinical Studies Submitted to the Food and Drug Administration 2000–2007American Journal of Therapeutics, 2010
- The Medical Device Safety Act of 2009New England Journal of Medicine, 2009
- Riegel v. Medtronic, Inc.: Revisiting Pre-Emption for Medical DevicesJournal of Law, Medicine & Ethics, 2009
- Testing New ICD TechnologyNew England Journal of Medicine, 2008
- Semper Fidelis — Consumer Protection for Patients with Implanted Medical DevicesNew England Journal of Medicine, 2008
- A Pivotal Medical-Device CaseNew England Journal of Medicine, 2008